• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Lancet Phase 2b REZOLVE-AD Data Could Be A Game Changer For Nektar Therapeutics (NKTR)

    Simply Wall St·09/07/2026 16:24:33
    Listen to the news
    • Nektar Therapeutics recently announced that The Lancet has published peer-reviewed 16-week Phase 2b REZOLVE-AD data for rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis, highlighting statistically significant efficacy, broad patient-reported benefits, and a differentiated safety profile versus placebo.
    • The data not only reinforce rezpegaldesleukin’s T-reg–targeted mechanism with biomarker evidence, but have also underpinned the design and dosing choices of Nektar’s ongoing global Phase 3 ZENITH AD program across induction and maintenance settings.
    • We’ll now examine how this Lancet-backed Phase 2b efficacy and safety profile for rezpegaldesleukin could reshape Nektar Therapeutics’ investment narrative.

    Find 47 companies with promising cash flow potential yet trading below their fair value.

    Nektar Therapeutics Investment Narrative Recap

    To own Nektar Therapeutics, you essentially need to believe that rezpegaldesleukin (REZPEG) can progress through late stage trials and become a cornerstone therapy in atopic dermatitis and other autoimmune diseases, despite the company being pre commercial and loss making. The Lancet publication strengthens the scientific and clinical rationale behind REZPEG and directly supports the Phase 3 ZENITH AD program, but it does not remove the near term risks around funding needs, dilution, and execution in late stage development.

    Among recent announcements, the May 2026 filing of a US$150 million at the market equity program stands out in this context. Combined with earlier follow on offerings, it underlines management’s reliance on equity capital while REZPEG advances through Phase 3. For investors, this matters because the stronger Phase 2b data could potentially support continued access to capital on less punitive terms, but it also highlights how closely the dilution risk is now tied to clinical and regulatory progress.

    Yet, against this promising clinical story, investors should still be aware of how extended cash burn and ongoing dilution risk could...

    Read the full narrative on Nektar Therapeutics (it's free!)

    Nektar Therapeutics' narrative projects $40.0 million revenue and $8.8 million earnings by 2029. This implies revenues declining by 9.9% per year and an earnings increase of about $165.9 million from -$157.1 million today.

    Uncover how Nektar Therapeutics' forecasts yield a $144.40 fair value, a 95% upside to its current price.

    Exploring Other Perspectives

    NKTR 1-Year Stock Price Chart
    NKTR 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming around 34.7 percent annual revenue growth and a swing to US$26.8 million in earnings by 2029, which is far more bullish than consensus and could look either more justified or overstretched once the full impact of the REZOLVE AD Lancet data and future Phase 3 outcomes are reflected in updated views.

    Explore 3 other fair value estimates on Nektar Therapeutics - why the stock might be worth over 2x more than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready For A Different Approach?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.